September 14, 2012
Mitsubishi Tanabe Pharma Corporation (MTPC) announced on September 13 that it filed for an additional indication of chronic atrial fibrillation on September 10 for the selective β 1 antagonist Maintate (bisoprolol). According to the company, there are at least one...read more